Could a single CAR-T infusion stop smoldering myeloma before it turns deadly?
NCT ID NCT05767359
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tests a CAR-T cell therapy called cilta-cel in 20 people with high-risk smoldering myeloma, a pre-cancer condition. The treatment uses a patient's own immune cells, modified to attack myeloma cells. The goal is to see if it is safe and can prevent or delay the disease from becoming active multiple myeloma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.